← Back to home

RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA(PTCL),CUTANEOUS T-CELL LYMPHOMA(CTCL),ADULT T-CELL LEUKEMIA/LYMPHOMA(ATLL)

Clinical trials for RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA(PTCL),CUTANEOUS T-CELL LYMPHOMA(CTCL),ADULT T-CELL LEUKEMIA/LYMPHOMA(ATLL) explained in plain language.

Never miss a new study

Get alerted when new RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA(PTCL),CUTANEOUS T-CELL LYMPHOMA(CTCL),ADULT T-CELL LEUKEMIA/LYMPHOMA(ATLL) trials appear

Sign up with your email to follow new studies for RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA(PTCL),CUTANEOUS T-CELL LYMPHOMA(CTCL),ADULT T-CELL LEUKEMIA/LYMPHOMA(ATLL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

New drug tested for Tough-to-Treat blood cancers

Disease control Terminated

This study tested a new drug called ASTX660 for people with T-cell lymphoma that has returned or not improved with other treatments. The main goals were to find a safe dose and see how well the drug worked. The trial was small and ended early, so it was a first step in understand…

Matched conditions: RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA(PTCL),CUTANEOUS T-CELL LYMPHOMA(CTCL),ADULT T-CELL LEUKEMIA/LYMPHOMA(ATLL)

Phase: PHASE1, PHASE2 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Mar 27, 2026 12:38 UTC

RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA(PTCL),CUTANEOUS T-CELL LYMPHOMA(CTCL),ADULT T-CELL LEUKEMIA/LYMPHOMA(ATLL)

Get alerted when new RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA(PTCL),CUTANEOUS T-CELL LYMPHOMA(CTCL),ADULT T-CELL LEUKEMIA/LYMPHOMA(ATLL) trials appear

New drug tested for Tough-to-Treat blood cancers